Description
This section will provide an overview and understanding of:
- Key stakeholders in the UK retail & hospital market
- Pricing and Reimbursement timelines in UK
- Key determinants, such as the QALY, influencing the reimbursement status and pricing potential of an asset
- Recent trends within cost-effectiveness assessments
- Extra funding pathways for hospital products, such as Cancer Drug Funds
- Opportunities to engage early with HTA bodies via early advice meetings
- Illustrative analogue cases showcasing assessment and pricing trends for specific therapeutic areas
